{"id":71604,"date":"2026-08-04T12:10:22","date_gmt":"2026-08-04T04:10:22","guid":{"rendered":"https:\/\/flcube.com\/?p=71604"},"modified":"2026-08-04T12:10:23","modified_gmt":"2026-08-04T04:10:23","slug":"sanofi-reports-17-8-revenue-growth-in-q2-2026-driven-by-dupixent-and-pharma-launches","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71604","title":{"rendered":"Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sanofi S.A.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>) announced second-quarter 2026 financial results, with net sales of <strong>EUR 11.6 billion<\/strong> (USD 13.4 billion), a <strong>17.8% increase at constant exchange rates (CER) year-over-year (YOY)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-financial-performance-summary\" class=\"wp-block-heading\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q2 2026<\/th><th>YOY Change (CER)<\/th><\/tr><\/thead><tbody><tr><td><strong>Net Sales<\/strong><\/td><td>EUR 11.6B (USD 13.4B)<\/td><td>+17.8%<\/td><\/tr><tr><td><strong>Pharma Launches Sales<\/strong><\/td><td>EUR 1.3B (USD 1.5B)<\/td><td>+48.3%<\/td><\/tr><tr><td><strong>Dupixent Sales<\/strong><\/td><td>EUR 5.2B (USD 6.0B)<\/td><td>+37.6%<\/td><\/tr><tr><td><strong>Vaccines Sales<\/strong><\/td><td>EUR 1.1B (USD 1.3B)<\/td><td>-4.7%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-business-segment-highlights\" class=\"wp-block-heading\">Business Segment Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pharma Launches<\/strong>: Increased by 48.3% to EUR 1.3 billion, driven mostly by <strong>Ayvakit<\/strong>, <strong>ALTUVIIIO<\/strong>, and <strong>Sarclisa<\/strong><\/li>\n\n\n\n<li><strong>Dupixent (dupilumab)<\/strong>: Sales grew 37.6% to EUR 5.2 billion, exceeding EUR 5 billion in a single quarter for the first time<\/li>\n\n\n\n<li><strong>Vaccines<\/strong>: Sales decreased by 4.7% to EUR 1.1 billion, impacted by a high basis of comparison in influenza vaccines<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-guidance-update\" class=\"wp-block-heading\">Strategic Guidance Update<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Based on strong performance in the first half and anticipating normalization of growth in the second half, Sanofi has upgraded its 2026 guidance:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sales Growth<\/strong>: Now expecting around <strong>10% at CER<\/strong> (upgraded from previous guidance)<\/li>\n\n\n\n<li><strong>Business EPS<\/strong>: Expected to grow <strong>slightly faster than sales<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-positioning\" class=\"wp-block-heading\">Market Context &amp; Competitive Positioning<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Sanofi&#8217;s exceptional Q2 performance demonstrates the company&#8217;s successful execution of its strategic transformation, with Dupixent continuing to exceed expectations as a blockbuster immunology asset. The 48.3% growth in pharma launches highlights the successful commercialization of recent product introductions across multiple therapeutic areas.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The slight decline in vaccines sales reflects challenging year-over-year comparisons rather than underlying business weakness, as the influenza vaccine market experienced exceptional demand in the prior year period.<\/p>\n\n\n\n<h2 id=\"h-forward-looking-statements\" class=\"wp-block-heading\">Forward-Looking Statements<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This brief contains forward-looking statements regarding financial performance, growth expectations, and business outlook. Actual results may differ due to market dynamics, competitive pressures, regulatory developments, and other risk factors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026-07-30-05-30-00-3335767-en.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026-07-30-05-30-00-3335767-en.\"><\/object><a id=\"wp-block-file--media-327bdd31-f6b2-46de-ab8a-8b31e5fec2aa\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026-07-30-05-30-00-3335767-en.pdf\">2026-07-30-05-30-00-3335767-en<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026-07-30-05-30-00-3335767-en.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-327bdd31-f6b2-46de-ab8a-8b31e5fec2aa\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi S.A. (NASDAQ: SNY) announced second-quarter 2026 financial results, with net sales of EUR 11.6&#8230;<\/p>\n","protected":false},"author":1,"featured_media":71606,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[27,867,147],"class_list":["post-71604","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-nasdaq-sny","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi S.A. (NASDAQ: SNY) announced second-quarter 2026 financial results, with net sales of EUR 11.6 billion (USD 13.4 billion), a 17.8% increase at constant exchange rates (CER) year-over-year (YOY).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71604\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches\" \/>\n<meta property=\"og:description\" content=\"Sanofi S.A. (NASDAQ: SNY) announced second-quarter 2026 financial results, with net sales of EUR 11.6 billion (USD 13.4 billion), a 17.8% increase at constant exchange rates (CER) year-over-year (YOY).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71604\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-04T04:10:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-04T04:10:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0401.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71604#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71604\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches\",\"datePublished\":\"2026-08-04T04:10:22+00:00\",\"dateModified\":\"2026-08-04T04:10:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71604\"},\"wordCount\":288,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71604#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0401.webp\",\"keywords\":[\"Finanical Reports\",\"NASDAQ: SNY\",\"Sanofi\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71604#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71604\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71604\",\"name\":\"Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71604#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71604#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0401.webp\",\"datePublished\":\"2026-08-04T04:10:22+00:00\",\"dateModified\":\"2026-08-04T04:10:23+00:00\",\"description\":\"Sanofi S.A. (NASDAQ: SNY) announced second-quarter 2026 financial results, with net sales of EUR 11.6 billion (USD 13.4 billion), a 17.8% increase at constant exchange rates (CER) year-over-year (YOY).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71604#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71604\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71604#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0401.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0401.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71604#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches - Insight, China&#039;s Pharmaceutical Industry","description":"Sanofi S.A. (NASDAQ: SNY) announced second-quarter 2026 financial results, with net sales of EUR 11.6 billion (USD 13.4 billion), a 17.8% increase at constant exchange rates (CER) year-over-year (YOY).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71604","og_locale":"en_US","og_type":"article","og_title":"Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches","og_description":"Sanofi S.A. (NASDAQ: SNY) announced second-quarter 2026 financial results, with net sales of EUR 11.6 billion (USD 13.4 billion), a 17.8% increase at constant exchange rates (CER) year-over-year (YOY).","og_url":"https:\/\/flcube.com\/?p=71604","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-04T04:10:22+00:00","article_modified_time":"2026-08-04T04:10:23+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0401.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71604#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71604"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches","datePublished":"2026-08-04T04:10:22+00:00","dateModified":"2026-08-04T04:10:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71604"},"wordCount":288,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=71604#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0401.webp","keywords":["Finanical Reports","NASDAQ: SNY","Sanofi"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71604#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71604","url":"https:\/\/flcube.com\/?p=71604","name":"Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=71604#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=71604#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0401.webp","datePublished":"2026-08-04T04:10:22+00:00","dateModified":"2026-08-04T04:10:23+00:00","description":"Sanofi S.A. (NASDAQ: SNY) announced second-quarter 2026 financial results, with net sales of EUR 11.6 billion (USD 13.4 billion), a 17.8% increase at constant exchange rates (CER) year-over-year (YOY).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71604#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71604"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=71604#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0401.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0401.webp","width":1080,"height":608,"caption":"Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71604#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0401.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71604"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71604\/revisions"}],"predecessor-version":[{"id":71607,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71604\/revisions\/71607"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/71606"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71604"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71604"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}